Results 61 to 70 of about 18,301 (299)

Assessing Dominance in Survival Functions: A Test for Right-Censored Data

open access: yesMathematics
This paper proposes a new statistical test to assess the dominance of survival functions in the presence of right-censored data. Traditional methods, such as the Log-Rank test, are inadequate for determining whether one survival function consistently ...
Félix Belzunce   +2 more
doaj   +1 more source

Description of survival data extended to the case of competing risks: a teaching approach based on frequency tables

open access: yesEpidemiology, Biostatistics and Public Health, 2022
Survival analysis is a powerful statistical tool to study failure-time data. In introductory courses students learn how to describe right-censored survival time data using the product-limit estimator of the survival function on a given end-point relying
Davide Paolo Bernasconi   +1 more
doaj  

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

open access: yesMolecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy   +10 more
wiley   +1 more source

Description of survival data extended to the case of competing risks: a teaching approach based on frequency tables

open access: yesEpidemiology, Biostatistics and Public Health, 2013
Survival analysis is a powerful statistical tool to study failure-time data. In introductory courses students learn how to describe right-censored survival time data using the product-limit estimator of the survival function on a given end-point relying ...
Davide Paolo Bernasconi, Laura Antolini
doaj   +1 more source

On the Kaplan–Meier Estimator of Long-Range Dependent Sequences

open access: yes, 2001
long-range dependence, censoring, Kaplan–Meier estimator, limiting distribution, multiple Wiener–Itô integrals,
Nikolai Leonenko   +3 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Análisis de supervivencia aplicado a la banca comercial venezolana, 1996 – 2004

open access: yesRevista Colombiana de Estadística, 2007
Se utiliza el análisis de supervivencia como técnica estadística para investigar cuándo es probable que una entidad financiera cambie de estado.
MARÍA ALEJANDRA AYALA   +2 more
doaj  

A COMPARISON OF NONPARAMETRIC ESTIMATORS FOR LENGTH DISTRIBUTION IN LINE SEGMENT PROCESSES

open access: yesImage Analysis and Stereology, 2019
We study nonparametric estimation of the length distribution for stationary line segment processes in the d-dimensional Euclidean space. Several methods have been proposed in the literature. We review different approaches (Horvitz-Thompson type estimator,
Zbynek Pawlas, Marketa Zikmundova
doaj   +1 more source

Understanding survival analysis: Kaplan-Meier estimate

open access: yesInternational Journal of Ayurveda Research, 2010
Kaplan-Meier estimate is one of the best options to be used to measure the fraction of subjects living for a certain amount of time after treatment. In clinical trials or community trials, the effect of an intervention is assessed by measuring the number of subjects survived or saved after that intervention over a period of time. The time starting from
Goel, Manish Kumar   +2 more
openaire   +3 more sources

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy